Suven Life secures 4 new patents
City-based Suven Life Sciences on Friday said it had secured four new patents from four different geographies for a drug used in the treatment of neuro-degenerative diseases.
Hyderabad: City-based Suven Life Sciences on Friday said it had secured four new patents from four different geographies for a drug used in the treatment of neuro-degenerative diseases.
“The grant of one product patent from Eurasia, one from Europe, one from Israel and one from Macau correspond to the New Chemical Entities for the treatment of disorders associated with neurodegenerative diseases,” Suven Life said in a release. The patents are valid till 2030.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO, Suven Life. With these new patents, Suven has 15 granted patents from Eurasia, 18 from Europe.
These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
